Standard Chem & Pharm (1720) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT
1.3B, trading at NT$63.50 on the TAI. This SniperIQ fundamentals page covers Standard Chem & Pharm's valuation (P/E 11.8x, P/B 2.4x), profitability (net margin 13.7%), revenue (NT$7.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
1.3B
P/E (TTM)11.8x
Net Margin13.7%
Revenue (FY25)NT$7.0B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Standard Chem & Pharm's market cap?
Standard Chem & Pharm (1720) has a market capitalization of approximately NT
1.3B, trading at NT$63.50 on the TAI. Market cap moves with the live share price.
What is Standard Chem & Pharm's P/E ratio?
Standard Chem & Pharm's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Standard Chem & Pharm?
Standard Chem & Pharm runs a net profit margin of 13.7%, a gross margin of 41.6%, and an operating margin of 19.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Standard Chem & Pharm generate?
Standard Chem & Pharm reported revenue of NT$7.0B for fiscal year 2025, with net income of NT$928M and earnings per share (EPS) of 5.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Standard Chem & Pharm pay a dividend?
Standard Chem & Pharm offers a trailing dividend yield of about 4.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Standard Chem & Pharm financially healthy?
Standard Chem & Pharm carries a debt-to-equity ratio of 0.19x and a current ratio of 2.05x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Standard Chem & Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Standard Chem & Pharm (1720) the key facts are: market cap NT
1.3B, P/E 11.8x, revenue NT$7.0B, 52-week range 53.5-66.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Standard Chem & Pharm's full fundamentals live
Get Standard Chem & Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.